MentionFox
Home › funding signals › Ansa Biotechnologies, Inc.
Form D · on the record

Ansa Biotechnologies — $54.40M Form D filing, November 2026

Before you sell to, join or invest in Ansa Biotechnologies, Inc.

MentionFox check on Ansa Biotechnologies, Inc.: only 1 source on file so far (checked 19 November 2026). Run a full check before you rely on it. mentionfox.com/c/funding/ansa-biotechnologies-inc-form-d-001596

Check Ansa Biotechnologies, Inc. before you sell to, join or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about Ansa Biotechnologies, Inc.?

Ansa Biotechnologies, Inc. filed a Form D with the Securities and Exchange Commission on 2026-11-18.

Ansa Biotechnologies, Inc. filed a Form D notice of an exempt securities offering with the SEC on November 18, 2026. The filing reports $54.40M sold. Its industry group is Biotechnology. It names Jason Gammack (Executive Officer, Director), Daniel Lin-Arlow (Executive Officer, Director), Yanniv Dorone (Director) (SEC Form D, November 18, 2026).

Sell to companies like Ansa Biotechnologies, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Ansa Biotechnologies, Inc. raised on Nov 18. 137 companies raised this week.

Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.

Linework USA INC.$1.2BAI and software
Linework USA INC.$326MAI and software
Pathos AI, Inc.$238MBiotech
Galvanize Therapeutics, Inc.$136MBiotech
Tractian Inc.$106MAI and software
Check one company free All companies that raised this week

Selling to Ansa Biotechnologies, Inc.? See who runs it and how to reach them, plus this week's 161 other newly funded companies.

Is this your company?

Key facts

Run the free check on Ansa Biotechnologies, Inc. →

Ansa Biotechnologies, Inc.

New Form D on file · 2026-11-18 · the record

$54.40M
raise on the record
D
filing
18
investors in
CALIFORNIA
based
Open the record →

What the record says

FilingForm D
Filed2026-11-18
Industry groupBiotechnology
Entity typeCorporation
Incorporated inDELAWARE
BasedEMERYVILLE, CALIFORNIA
CIK1816722
Accession0001231919-26-001596

Pitching, partnering or investing alongside them? See who really runs and owns Ansa Biotechnologies, Inc.

Free to see. No signup.

What do you want to do with Ansa Biotechnologies, Inc.?

Get the full cited report on Ansa Biotechnologies, Inc.

What the filing shows about Ansa Biotechnologies, Inc.

  • 18 investors had already put money in when it filed.
  • The filing names 10 people as officers, directors or promoters.

Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on Ansa Biotechnologies, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

See a sample report

Just raised? Your investors will ask for updates.

The weeks after a raise are when investors, other founders and press look Ansa Biotechnologies, Inc. up. FoxPlug is your startup's chief of staff: it reads your whole stack and tells you what to fix, what to say and what to skip, for founders shipping with Claude Code, Codex or Cursor. It drafts your monthly investor update from your real numbers, and its free tools need no account. GetFoxChat puts an AI operator on Ansa Biotechnologies, Inc.'s own site, named as you like, so the visitors this record sends you don't read one page and leave.

Who the filing names, and in what role

The filing gives Ansa Biotechnologies, Inc.'s address as 1198 65TH Street #250, Emeryville, CA 94608.

What the filing says

  • Offered: $71,903,290. Sold: $54,403,290. Left to sell: $17,500,000. (filing)
  • Investors: 18 had already invested. (filing)
  • Date of first sale: October 16, 2026. (filing)
  • Types of securities: Equity. (filing)
  • Item 16: the filing reports that none of the proceeds goes to executive officers, directors or promoters. (filing)

This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.

Order the Full Report on Ansa Biotechnologies, Inc. See pricing

Is Ansa Biotechnologies, Inc. a real, registered company?

Ansa Biotechnologies, Inc. is a registered filer with the SEC (CIK 1816722) and has filed since 2025-10-02. 3 filings are on record, the latest on 2026-11-18.

A filing shows the company exists and what it reports about itself. It is not an audit or a rating.

Who runs Ansa Biotechnologies, Inc.?

Ansa Biotechnologies, Inc.'s Form D of 2026-11-18 names Jason Gammack, Daniel Lin-Arlow, Yanniv Dorone and 7 more as its officers, directors or promoters.

How much has Ansa Biotechnologies, Inc. raised?

Its new offerings report $99.60M sold across 2 offerings, as its own filings state.

Filing history · 3 filings on this registrant
Form D · 2025-10-02 · $45.20MForm D/A, amended · 2025-12-10 · $46.45MForm D · 2026-11-18 · $54.40M · this page 2025-10-02 2026-11-18

A hollow marker is an amendment (Form D/A); a solid one is an original Form D. The larger marker is the filing this page is about.

Biotechnology · by week
This raise, $54.40M, filed week of Nov 16

Trailing twelve months. 758 filings in Biotechnology, totalled by week. The dot is this raise, $54.40M, on the same scale — one filing against the whole group's total, so it sits low by construction.

Want the whole picture on Ansa Biotechnologies, Inc.?

What the filing shows about Ansa Biotechnologies, Inc.

  • 18 investors had already put money in when it filed.
  • The filing names 10 people as officers, directors or promoters.

Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on Ansa Biotechnologies, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Ansa Biotechnologies, Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    1 cited source found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

The full profile

Checking your access…

Sourced from the filing index on sec.gov.

Follow this companyRSS

Tools for this story

Each opens in a new tab, filled in for Ansa Biotechnologies, Inc.. With no account yet, you sign up free and land on the result.

Share this page

Is this your company?

Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.

Ansa Biotechnologies, Inc.: Raised $54.40M, Form D filed 2026-11-18
Share on LinkedIn Share on X Download image

Cite this page

Permanent URL: https://mentionfox.com/funding/ansa-biotechnologies-inc-form-d-001596
Last updated 2026-11-19
Primary record: SEC filing 1 · SEC filing 2
Ansa Biotechnologies raised $54.40M — SEC Form D filing, November 2026. MentionFox, 2026-11-19. https://mentionfox.com/funding/ansa-biotechnologies-inc-form-d-001596